This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Galapagos Nv. Scipher Medicine Total cash consideration of up to €134 million o €129 million cash payment o earnout of €5 million upon achievement of revenue target … Galapagos : Publication of the annual report and invitation to the ... Investors: Elizabeth Goodwin VP Investor Relations +1 781 460 1784. Investor Relations Manager. Send e-mail. In 2020, Galapagos brought its first medicine to patients in Europe. Mechelen, Belgium; 1 June 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. We look forward to host you on June 13th. Galapagos is progressing multiple programs in inflammation, fibrosis, and kidney diseases. Galapagos is listed on Euronext Amsterdam and Brussels and on the NASDAQ, all with the ticker symbol GLPG. We have an international investor base, with a long term commitment to the biotech industry. VP-Corporate Communications & Investor Relations--Marie-Théodora Vandewiele: Secretary--Andre Hoekema, Dr. Chief Business Officer: 63-Michele Manto: Senior Vice President-Commercial Operations-2017: Sandra Cauwenberghs, Dr. Director-Investor Relation--Phil Dudfield: Managing Director-Fidelta-- 01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos NV (0JXZ) Financials - LTS | Morningstar Investors Galapagos NV forms part of the Bel20 index (top 20 listed companies) on Euronext Brussels, the AEX Index (top 25 listed companies) on Euronext Amsterdam, and the Nasdaq … GLPG Stock - Galapagos Nv SEC Filings

Traueranzeigen Hohenloher Zeitung, رؤية السماء سوداء في المنام للمتزوجة, Geros Flohmarkt Tübingen Festplatz 2020, Articles G